Picture3.jpg
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
February 01, 2024 08:15 ET | Clearmind Medicine Inc.
The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver,...
Picture3.jpg
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
January 16, 2024 11:19 ET | Clearmind Medicine Inc.
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel...
Picture3.jpg
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
January 11, 2024 09:28 ET | Clearmind Medicine Inc.
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel...
Picture3.jpg
Clearmind Medicine Completed Type A Meeting with the FDA
January 10, 2024 07:18 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Picture3.jpg
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
January 04, 2024 07:18 ET | Clearmind Medicine Inc.
The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA Tel Aviv,...
Picture3.jpg
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
December 14, 2023 08:26 ET | Clearmind Medicine Inc.
Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been CuredTel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Picture3.jpg
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
December 05, 2023 08:47 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Picture3.jpg
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023 08:14 ET | Clearmind Medicine Inc.
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program Tel Aviv, Israel / Vancouver, Canada, Dec. 01, 2023 (GLOBE...
Picture3.jpg
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
November 28, 2023 08:25 ET | Clearmind Medicine Inc.
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite Tel Aviv, Israel / Vancouver, Canada, Nov. ...
Picture3.jpg
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
November 27, 2023 08:55 ET | Clearmind Medicine Inc.
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space Tel Aviv,...